SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The...
Covered in this story
Analyst targets on Pacira Biosciences Inc
- Jefferies: $36.4 → $36 by Oct 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PCRX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pacira Biosciences Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.